Insider Transactions in Q1 2024 at Corcept Therapeutics Inc (CORT)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 27
2024
|
Sean Maduck |
SELL
Open market or private sale
|
Direct |
25,953
-23.34%
|
$648,825
$25.01 P/Share
|
|
Mar 27
2024
|
Sean Maduck |
BUY
Exercise of conversion of derivative security
|
Direct |
25,953
+18.93%
|
$77,859
$3.88 P/Share
|
|
Mar 19
2024
|
Sean Maduck |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+10.5%
|
$20,000
$2.61 P/Share
|
|
Mar 18
2024
|
Sean Maduck |
SELL
Open market or private sale
|
Direct |
17,219
-18.63%
|
$430,475
$25.0 P/Share
|
|
Mar 18
2024
|
Sean Maduck |
BUY
Exercise of conversion of derivative security
|
Direct |
17,219
+15.7%
|
$51,657
$3.88 P/Share
|
|
Mar 01
2024
|
Joseph Douglas Lyon |
BUY
Grant, award, or other acquisition
|
Direct |
1,014
+6.71%
|
$12,168
$12.03 P/Share
|
|
Mar 01
2024
|
Joseph Douglas Lyon |
SELL
Payment of exercise price or tax liability
|
Direct |
474
-7.0%
|
$11,376
$24.06 P/Share
|
|
Mar 01
2024
|
Sean Maduck |
BUY
Grant, award, or other acquisition
|
Direct |
1,272
+0.84%
|
$15,264
$12.03 P/Share
|
|
Mar 01
2024
|
Sean Maduck |
SELL
Payment of exercise price or tax liability
|
Direct |
505
-0.68%
|
$12,120
$24.06 P/Share
|
|
Mar 01
2024
|
William Guyer Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
604
-9.09%
|
$14,496
$24.06 P/Share
|
|
Mar 01
2024
|
Daniel N Swisher Jr |
SELL
Open market or private sale
|
Direct |
2,200
-100.0%
|
$50,600
$23.59 P/Share
|
|
Mar 01
2024
|
Daniel N Swisher Jr |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+50.0%
|
$11,000
$5.86 P/Share
|
|
Mar 01
2024
|
Atabak Mokari Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,108
+5.65%
|
$13,296
$12.03 P/Share
|
|
Mar 01
2024
|
Atabak Mokari Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
517
-5.78%
|
$12,408
$24.06 P/Share
|
|
Mar 01
2024
|
Gary Charles Robb Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,394
+3.39%
|
$16,728
$12.03 P/Share
|
|
Mar 01
2024
|
Gary Charles Robb Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
656
-3.37%
|
$15,744
$24.06 P/Share
|
|
Feb 16
2024
|
Joseph Douglas Lyon |
SELL
Open market or private sale
|
Direct |
1,000
-12.86%
|
$26,000
$26.0 P/Share
|
|
Feb 16
2024
|
Joseph Douglas Lyon |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+11.4%
|
$11,000
$11.35 P/Share
|
|
Feb 16
2024
|
Sean Maduck |
SELL
Open market or private sale
|
Direct |
27,068
-26.66%
|
$676,700
$25.97 P/Share
|
|
Feb 16
2024
|
Sean Maduck |
BUY
Exercise of conversion of derivative security
|
Direct |
27,068
+12.56%
|
$81,204
$3.59 P/Share
|
|
Feb 15
2024
|
Sean Maduck |
SELL
Open market or private sale
|
Direct |
4,760
-6.01%
|
$119,000
$25.0 P/Share
|
|
Feb 15
2024
|
Sean Maduck |
BUY
Exercise of conversion of derivative security
|
Direct |
4,760
+5.67%
|
$14,280
$3.29 P/Share
|
|
Feb 01
2024
|
Daniel N Swisher Jr |
SELL
Open market or private sale
|
Direct |
2,200
-100.0%
|
$48,400
$22.0 P/Share
|
|
Feb 01
2024
|
Daniel N Swisher Jr |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+50.0%
|
$11,000
$5.86 P/Share
|
|
Jan 08
2024
|
Hazel Hunt Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
29,792
-24.19%
|
$804,384
$27.46 P/Share
|
|
Jan 08
2024
|
Hazel Hunt Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+28.88%
|
$150,000
$3.02 P/Share
|
|
Jan 02
2024
|
Daniel N Swisher Jr |
SELL
Open market or private sale
|
Direct |
2,200
-100.0%
|
$48,400
$22.11 P/Share
|
|
Jan 02
2024
|
Daniel N Swisher Jr |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+50.0%
|
$11,000
$5.86 P/Share
|